SeraCare Life Sciences Launches First-to-Market HPV Genotype Performance Panel

MILFORD, Mass.--(Business Wire)--
SeraCare Life Sciences, Inc. (NASDAQ: SRLS) today announced that the Company has
launched a new product in its diagnostic controls and panels portfolio-the
SeraCare Human Papillomavirus (HPV) Genotype Performance Panel. This panel is
the first product on the market to enable testing laboratories, researchers and
diagnostic manufacturers to validate their entire HPV testing system, ensuring
that testing systems can differentiate between high- and low-risk HPV genotypes.
In addition, the panel contains members specific for HPV type 16 and 18, strains
that lead to nearly 70% of cervical cancer cases, to allow for the evaluation of
newer HPV testing systems that can distinguish these two high-risk viruses.
Adoption of the panel will provide users with the most complete information
available to evaluate HPV test kit efficacy and to guide more informed treatment
decisions.

Studies have shown that testing for HPV, the virus that can lead to cervical
cancer, is the most effective way to reduce the incidence of cervical cancer
when compared to Pap testing and that a single round of molecular HPV testing
significantly reduces the number of advanced cervical cancers and deaths. Based
on these data, there has been a dramatic rise in diagnostic testing for HPV,
resulting in a need for more comprehensive controls and panels to verify the
accuracy of HPV testing. SeraCare`s HPV Performance Panel is compatible with a
number of widely-used HPV DNA tests, including tests manufactured by Qiagen®,
Hologic™ and Roche™.

"SeraCare is pleased to have met our 2009 corporate objective to introduce the
market`s first comprehensive HPV Performance Panel," said Susan Vogt, President
and Chief Executive Officer of SeraCare. "This is a key component of our growth
strategy because HPV testing is one of the largest and fastest growing segments
within molecular diagnostics today. The HPV panel also marks the third new
product offering we have introduced this year to improve the testing and
treatment of serious diseases in high-value research and therapeutic areas. We
believe these new products will contribute to SeraCare`s near-term goal of
achieving and sustaining operating profitability."

About SeraCare Life Sciences:

SeraCare serves the global life sciences industry by providing vital products
and services to facilitate the discovery, validation and production of human
diagnostics and therapeutics. SeraCare`s innovative portfolio includes
diagnostic controls, plasma-derived reagents and molecular biomarkers,
biobanking and contract research services. SeraCare's quality systems,
scientific expertise and state-of-the-art facilities support its customers in
meeting the stringent requirements of the highly regulated life sciences
industry.

Forward-Looking Statement:

This press release contains disclosures that are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 about
SeraCare Life Sciences, Inc. ("SeraCare" or the "Company"). All statements
regarding our expected future financial position, results of operations, cash
flows, dividends, financing plans, business strategy, budget, projected costs or
cost savings, capital expenditures, competitive positions, growth opportunities
for existing products or products under development, plans and objectives of
management for future operations and markets for stock are forward-looking
statements. In addition, forward-looking statements include statements in which
we use words such as "expect," "believe," "anticipate," "intend," or similar
expressions. Although we believe the expectations reflected in such
forward-looking statements are based on reasonable assumptions, we cannot assure
you that these expectations will prove to have been correct, and actual results
may differ materially from those reflected in the forward-looking statements.
Factors that could cause our actual results to differ from the expectations
reflected in the forward-looking statements in this press release include, but
are not limited to, failure to maintain proper inventory levels, availability of
financing, covenant limitations in our existing credit facility, reductions or
terminations of government or other contracts, interruption in our supply of
products or raw materials, actions of SeraCare's competitors and changes in the
regulatory environment. Many of these factors are beyond our ability to control
or predict.

SeraCare Life Sciences, Inc.
Gregory A. Gould, 508-244-6400
Chief Financial Officer
or
MacDougall Biomedical Communications
Sarah Cavanaugh, 781-235-3060
Investor Relations

Copyright Business Wire 2009